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Abstract
Background: Schistosomiasis is a neglected tropical disease burdening millions of people. One drug, praziquantel,
is currently used for treatment and control. Clinically relevant drug resistance has not yet been described, but there
is considerable heterogeneity in treatment outcomes, ranging from cure to only moderate egg reduction rates. The
objectives of this study are to investigate potential worm-induced dysbacteriosis of the gut microbiota and to assess
whether a specific microbiome profile could influence praziquantel response.
Methods: Using V3 and V4 regions of 16S rRNA genes, we screened the gut microbiota of 34 Schistosoma mansoni
infected and uninfected children from Côte d’Ivoire. From each infected child one pre-treatment, one 24-hour and one
21-day follow-up sample after administering 60 mg/kg praziquantel or placebo, were collected.
Results: Overall taxonomic profiling and diversity indicators were found to be close to a “healthy” gut structure in all
children. Slight overall compositional changes were observed between S. mansoni-infected and non-infected children.
Praziquantel treatment was not linked to a major shift in the gut taxonomic profiles, thus reinforcing the good
safety profile of the drug by ruling out off-targets effects on the gut microbes.16S rRNA gene of the Fusobacteriales
order was significantly more abundant in cured individuals, both at baseline and 24 hours post-treatment. A real-time
qPCR confirmed the over-abundance of Fusobacterium spp. in cured children. Fusobacterium spp. abundance could
also be correlated with treatment induced S. mansoni egg-reduction.
Conclusions: Our study suggests that neither a S. mansoni infection nor praziquantel administration triggers a significant
effect on the microbial composition and that a higher abundance of Fusobacterium spp., before treatment, is associated
with higher efficacy of praziquantel in the treatment of S. mansoni infections.
Trial registration: International Standard Randomised Controlled Trial, number ISRCTN15280205.
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Microbiome-drug interaction
Background
Schistosomiasis belongs to the group of neglected tropical
diseases caused by parasitic worms of the genus Schistosoma
[1]. Schistosomes have accompanied mankind for thousands
of years and - still today - they are pervasive where poverty
prevails [2, 3]. Recent estimates suggest that approximately
200 million people are affected by schistosomiasis [1].
Left untreated, the disease becomes chronic and debili-
tating and is therefore known as one of the diseases that
perpetuate the “poverty trap” [4, 5]. Schistosoma mansoni
inhabits the mesenteric veins of the gut and, by releasing
eggs, triggers a host cellular immune response, causing a
wide range of clinical manifestations including serious gut
inflammation [1]. Similarly, to other parasitic worms, they
interact and affect the same environment as the gut micro-
biota [6, 7].
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Treatment options against schistosomiasis are limited
to only one drug, namely, praziquantel. Developed in the
mid-1970s, praziquantel remains poorly characterized.
Its mechanism of action is not well understood and
pharmacokinetic/dynamic relationships have not yet been
determined [8, 9]. Remarkably, there is considerable hetero-
geneity in treatment outcomes, yet the link to any type of
resistance mechanism remains elusive [1, 10, 11]. Hence, it
is possible that the efficacy of praziquantel is dependent on
a variety of factors, including - but not limited - to hosts
genetic background, differences in the drug disposition and
bioavailability, and the gut microbiota [6, 7].
Several studies have aimed at characterizing the micro-
biome from different parts of the human body and have
shown considerable variation from one individual to
another [12–14]. The gut microbiome is composed of
hundreds of different microorganisms, including eukaryotic
parasites, bacteria and viruses [15–17]. Bacteria are the
most predominant type, with approximately 300 to 1000
different species in the intestine, and account for a large
majority of the genetic material present in stool [16, 18, 19].
Recent studies have shown that specific composition of the
microbiota, i.e. species diversity as well as relative
abundance, modulates the metabolism and disposal of
xenobiotics [20–24].
In this study, we investigate the associations between
S. mansoni, praziquantel and the gut microbial composition
in the framework of a randomized, controlled, dose-finding
and pharmacokinetic trial of praziquantel in preschool-
aged and school-aged children. Samples were analysed
to explore differences in microbial composition between
(i) infected and non-infected children, (ii) those receiving
praziquantel versus placebo, and (iii) those for which treat-
ment with praziquantel resulted either in successful or
unsuccessful clearance of worms.
Methods
Sample collection
The stool samples used in this study were sourced from
a praziquantel dose-finding clinical trial in school-aged
and pre-school-aged in Côte d’Ivoire [25]. Briefly, the
clinical trial was executed between November 2014 and
February 2015 in five villages located in the health district
of Azaguié, southern Côte d’Ivoire. Schistosoma mansoni-
positive children (n = 317; 2–15 years) as confirmed by
quadruplicate Kato-Katz smears from 2 stool samples were
eligible to participate in this trial and randomized to 20, 40
or 60 mg/kg praziquantel or placebo. For this study, a sub-
set of samples from 34 children treated with 60 mg/kg were
selected for microbial analysis. Children had been tested for
Ascaris lumbricoides, hookworm and Trichuris trichuria,
and those who were co-infected with either of these para-
sites were not included in the subset of 34 children ana-
lysed in this study. Children who received anthelminthic or
antimalarial treatment, or presented symptoms of a sys-
temic disease 4 weeks prior to this study were excluded.
From each child, stool samples were collected prior to
treatment (labelled with “A”), 24 hours post-treatment
(labelled with “B”) and 3 weeks post-treatment (labelled
with “C”), and a total of 96 stool samples were analysed.
Samples from each of these time-points were selected
according to four different conditions (see Table 1): (1)
non-infected children; (2) S. mansoni infection and cure
of children following 60 mg/kg praziquantel adminis-
tration; (3) S. mansoni infection and children not cured
following 60 mg/kg praziquantel administration; (4)
children infected with S. mansoni receiving a placebo.
The S. mansoni-positive groups (Groups 2–4) were fur-
ther stratified according to infection intensity as defined
by the World Health Organization (WHO) guidelines for
classification of schistosomiasis: (i) high (over 400 eggs
per gram (epg) of stool); (ii) moderate (100–399 epg); or
(iii) low (1–99 epg) [26]. We included children character-
ized by different infection intensities (Table 1).
The subset of children was selected based on the avail-
ability of (i) complete metadata and demographic informa-
tion, (ii) all parasitology test results, and (iii) the three
stool samples, at all three sampling times.
Pre-schoolers (3–5 year-old) had a Body Mass Index
(BMI) ranging from 12.7 to 21 and school-aged children
(5–13 year-old) had a BMI ranging from 14.7 to 32.2.
Detailed information is summarized in Additional file 1:
Table S1. According to thresholds set by the WHO, growth
indicators indicate that nutritional stunting is not occurring
in the subset of children involved in this study and that the
potential impact of malnutrition on the gut microbiota can
be ruled out.
DNA isolation
For each sample, 150 mg of faecal material was used to
isolate genomic DNA. DNA isolation was conducted with
the QIAamp DNA Stool kits (Qiagen, Hilden, Germany)
according to the manufacturers’ recommendations. Ex-
tracted DNA was eluted in 50 μl of the elution buffer and
used for downstream analyses. Concentrations were mea-
sured with a Qubit 3.0 fluorometer using a dsDNA High-
sensitivity Assay kit (Thermo Fisher Scientific, Waltham,
MA, USA). All concentrations are indicated in Additional
file 2: Table S2.
16S amplicon polymerase chain reaction (PCR)
Isolated DNA (2.5 μl) was used to perform amplification
of the V3-V4 region using the following primer pair,
according to Klindworth et al. [27]: forward (5'-TCG
TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG
CCT ACG GGN GGC WGC AG-3'); reverse (5'-GTC
TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA
GGA CTA CHV GGG TAT CTA ATC C-3').
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The reaction was performed in 25 μl reaction volumes
using the 2X KAPA HiFi HotStar ReadyMix (KAPA
Biosystems, Boston, MA, USA). The thermocycler was
set to the following parameters: 95 °C for 3 min, 25
cycles of 95 °C (30 s), 55 °C (30 s) and 72 °C (30 s), one
additional step at 72 °C (5 min) and finally set on hold
indefinitely at 4 °C. The quality of the amplified product
was controlled visually on a 1% agarose gel. The ampli-
cons were purified with an AMPure XP beads (Beckman-
Coulter, Fullerton, CA, USA) protocol.
Sequencing
The barcoding PCR was performed using primer pairs
from the Nextera XT Index kit (Illumina, San Diego,
CA, USA) to produce 96 amplicon pools with different
tags. The amplification reaction was conducted with the
same reagents and the thermocycler was set to the fol-
lowing parameters: 95 °C for 3 min, 20 cycles of 95 °C
(30 s), 55 °C (30 s), 72 °C (30 s), one additional step at
72 °C (5 min) and a final step at 4 °C until further pro-
cessing. Similarly to the first PCR, amplified products
were cleaned with AMPure XP beads. The quality of the
product was assessed using a 1% agarose gel and the
quantification was performed using a Qubit 3.0 Fluorimeter
(Thermo Fisher Scientific, Waltham, MA, USA) and the
corresponding High-sensitivity dsDNA HS Assay Kit. The
96 amplicon samples were pooled together in an equimolar
way and loaded on a cartridge on the Illumina MiSeq
sequencing system (Illumina, USA). MiSeq Reagent Kit
V3 (2 × 300 bp) sequencing reagents (Illumina, USA)
were used for this experiment.
Fusobacterium spp. quantitative real-time PCR (qPCR)
Fusobacterium spp. was amplified using the primers and
Taqman probes as described in Martin et al. [28]. DNA from
Fusobacterium nucleatum was obtained from the German
Collection of Microorganisms and Cell Cultures
(DSMZ). Briefly, 2 μl of isolated DNA was used to perform
the amplification of a conserved region of the 16S rDNA of
the genus Fusobacterium (including F. nucleatum, F. period-
onticum, F. alocis and F. simiae). The experiment was con-
ducted in 20 μl reaction volumes using the KAPA HiFi
Universal kit (KAPA Biosystems, USA). Thermocycling con-
ditions were set as follows: 50 °C for 2 min, 95 °C (10 min)
and 40 cycles of 15 s at 95 °C and 1 min at 60 °C. Amplifica-
tion was performed on a ViiA 7 Real-Time PCR System
(Applied Biosystems, Foster City, USA). All samples were
tested in triplicates. For normalization, total DNA was
measured using a Qubit 3.0 fluorometer combined with a
dsDNA High-sensitivity Assay kit (Thermo Fisher Scientific,
Waltham, MA, USA). QPCR Ct values were normalized by
input material using the following formula:
Ctmeasured− logefficiency  dilution factorð Þ ¼ Ctnorm
Ct values were further converted into concentrations
and subsequently into a theoretical copy numbers using
the following formula:
Exp Ctnorm‐bð Þ=aÞ NA
 
= Fusobacteriumbp  1 10^
9
 
MWbp
 
All resulting values were compared using the Mann-
Whitney U-test.
Data processing and statistical analysis
Raw datasets were fed into the QIIME pipeline [29] with
standard OTU (operational taxonomic unit) picking
parameters in closed-reference mode. Alpha and beta
diversities were computed using a rarefaction depth of
10,800 sequences. Resulting abundance tables were
analysed using the LefSe pipeline [30]. Briefly, a first
step compared the relative abundance of all identified
taxa between population groups using the Kruskal-
Wallis test. In case of statistical significance (P < 0.05),
Table 1 Summary of participants investigated in this study. Each child provided a sample before, 24 hours after and 3 weeks after
treatment with single dose (60 mg/kg) dose of praziquantel. For the placebo controls, samples were collected at the same time points
S. mansoni infection Infection intensity (epg) Treatment outcome No. of participants Sample identifiers Group name
Negative 0 Not applicable 6 1; 12; 13; 14; 15; 25 Controls
Positive 1–99 Cure 0 Cure
100–399 5 11; 17; 22; 26; 28
> 400 4 2; 7; 16; 27
1–99 Not cured 3 19; 23; 32 Not cured
100–399 3 10; 30; 31
> 400 2 5; 8
1–99 Placebo 3 20; 29; 34 Placebo
100–399 5 6; 18; 21; 24; 33; 1
> 400 3 3; 4; 9
Abbreviation: epg eggs per gram stool
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a pairwise Wilcoxon test was conducted to analyse whether
the feature is evenly distributed among individuals of the
same group but with different demographic characteristics
(e.g. different age, sex). All variables passing both tests are
ranked using a Linear Discriminant Analysis model by their
relative differences among groups.
Results
Composition of the gut microbiota in pre-treatment samples
at the phylum and family levels
Pre-processing, including filtering and de-noising of the
sequence datasets resulted in the analysis of a total of
4,160,032 sequences for 34 baseline samples with an
average of 122,353 (Standard deviation: 74,507) sequences
per sample. Results, presented at the phylum (Fig. 1a) and at
the family (Fig. 1b) level of resolution are stratified according
to infection intensities (negative, low, moderate and high).
Across all groups, the phyla Firmicutes and Bacteroidetes
were the most abundant (> 50%), except in one sample
from the low-intensity infection group (sample 34A) and
two from the high-intensity infection group (samples 5A
and 8A). The minimum and maximum observed abun-
dance of Firmicutes were 5.9% and 86.5%, respectively.
For the Bacteroidetes, the range spanned from 1.9% up
to 64.2%. The ratio Firmicutes over Bacteroidetes
remained above one across all but 6 samples (samples
6A, 18A, 19A, 23A, 24A and 30A). All 6 samples with
ratios lower than one were found among the group of
schistosome-infected individuals. The Proteobacteria
phylum was the third most abundant taxon, with a me-
dian of 7.71% across all samples. While the relative
abundance of this group was low in the control group
(non-infected children), with a median of 3.69% (mini-
mum of 1%; maximum of 20%), the median value in
children infected with S. mansoni was 9.04% (minimum
of 0.9%; maximum of 87%). The ratio of Firmicutes
over Proteobacteria was above one in all except for 6
samples from the infected group (samples 5A, 8A, 22A,
24A, 29A and 34A). The ratio of Bacteroidetes over
Proteobacteria was below one in the same samples,
along with 6 additional samples from the Schistosoma-
positive group (samples 7A, 10A, 20A, 28A, 32A and
33A). A final observation at the phylum level was the
presence of Actinobacteria and Verrucomicrobia with a
median of 0.9% and 0.1%, respectively. At the family
level, the abundance of Enterobacteriaceae, a subgroup
of the phylum Proteobacteria that contains numerous
pathogens, reached a maximum of 20% in the control
group (minimum of 2.6%) whereas in infected children,
the abundance of the same family was as high as 87.6%
of the overall composition. The abundance of members
from the family Prevotellaceae was highly heterogeneous
among the different groups, ranging from 1.6 to 56.2%.
Comparison of the gut microbiota in S. mansoni-infected
and non-infected children
Differences between infected and non-infected individuals
were explored using the LefSe pipeline. Figure 2 shows the
abundances of the different taxonomic groups between in-
fected and non-infected samples.
Differentiating abundances between these groups are
largely observable among the Proteobacteria. Bacteria
from the genus Klebsiella and Enterobacter arachidis
were significantly more abundant in children infected
with S. mansoni (P < 0.05). Over-abundance of members
from the families Cerasicoccaceae, Anaeroplasmataceae,
Campylobacteraceae and Peptococcaceae, and of the genus
Fructobacillus seem to be significantly linked to the faecal
microbiome of schistosome-negative children (P < 0.05).
Comparison of the gut microbiota diversity among the
different treatment groups
In Fig. 3, we present the different indicators commonly
used to assess microbial diversity, obtained with the QIIME
pipeline.
Although the diversity was lower in infected children,
the range of diversity indicators was more heterogeneous
in that group than in uninfected children. The variability
in control samples at both sampling times (0 h and
24 h) ranged between 25.9–50.9, 419.1–742.1, 4.4–
6.51 and 681.3–1147.8 for phylogenetic diversity, ob-
served species, Shannon’s index and Chao 1 index,
respectively. Identical indicators range between 19.2–
50.1, 217.8–837.8, 4.5–7.0 and 352.6–1285 in samples
from infected children, both at baseline and 24 h
post-treatment. We did not observe any age-related
differences (pre-school vs school-aged children).
Association between praziquantel treatment and the gut
microbiota composition
For the 34 samples collected 24 hours after treatment,
sequencing resulted in the analysis of a total of
4,595,622 reads, with an average of 135,165 curated
reads (Standard deviation: 81,880) per sample. To eluci-
date the potential off-target effects of praziquantel on
the microbiota composition, 24-hour samples from
those who received praziquantel (non-cured) versus
those that received placebo were analysed. The taxo-
nomic representation of the differential abundances is
presented in Fig. 4.
Comparison of both treatment groups highlighted a
few differences including a higher abundance of Bacilli
and Erysipelotrichi taxa in volunteers who received
praziquantel while some bacteria from the ML615J_28
order and the genus Actinobacillus were more abundant
in the placebo group.
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Comparison of the gut microbiota of individuals with
different praziquantel treatment outcomes
Infected children were categorized after administration
of a single dose of praziquantel in two groups, namely,
(i) cured and (ii) not cured. Figure 5 summarizes the main
differences between both groups.
For samples collected at baseline, before treatment,
there was an overabundance of members from the classes
Fusobacteriales, Rickettsiales and Neisseriales in volunteers
with high treatment efficacy. In contrast, individuals that
were not cured, harbored in their microbiome a higher
abundance of bacteria belonging to the genus Weissella.
There was a significantly higher abundance of members
from the class Fusobacteriales as well as of members from
the genera Clostridium and Actinobacillus in cured
volunteers, 24 hours after administration of praziquantel.
At this time point, in children characterized by treatment
failure, there was an overabundance of members from the
class Bacilli. We used qPCR to confirm the results
observed by 16S PCR for the family Fusobacteriaceae, by
selecting an assay to detect Fusobacterium spp., the most-
represented genus from this family in our dataset (Fig. 6).
Fig. 1 Composition of the microbiota of pre-treatment samples at two taxonomic levels. This bar chart shows the composition of the most abundant
bacterial groups of each patient, both at the phylum level (a) as well as at the family level (b)
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The measured qPCR efficiency, on the DNA of
Fusobacterium nucleatum was 91.5%. Fluorimeter quan-
tification of qPCR input is shown in Additional file 1:
Table S1. Fusobacterium spp. is significantly more
abundant in cured children before treatment (P =
0.018). The median normalized cycle threshold (Ct) in-
crease was +2.42 cycles between pre- and 24 hours
post-treatment in fully cured children, equivalent to a
median decrease in copy number is of -11,091 copies.
In the population of children for which the treatment
failed, the Ct value remained stable over the 24 h
period, with a median of -0.17 cycles. The median Ct was
29.37 and 29.72 in the cured and non-cured groups,
respectively, in the 24 hours post-treatment samples.
We compared the Ct values in placebo samples, to see
whether associations exist between egg reduction rate
and Fusobacterium spp. abundance. In the samples that
showed an increase in Fusobacterium spp. abundance
over the 24 hours (n = 5 samples; median = +1.21 cycle),
the percentage of remaining eggs at follow-up was 66%
while in those who had a decrease in Fusobacterium spp.
abundance (n = 6 samples; median = -3.02 cycle), the
average percentage of remaining eggs in the follow-up
samples was 34%.
Fig. 2 The gut microbiome composition differences in samples collected from S. mansoni negative and positive children at baseline. a
Quantitative representation of the differences in the gut microbial composition of both groups using a bar chart representation and an LDA
model (P < 0.05). b Taxonomic representation of significantly different relative abundances. Discriminative features (P < 0.05) are observed at
various taxonomic levels
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Fig. 3 Indicators of microbial diversity in control and infected samples, both before and 24 hours after treatment. a Faith’s Phylogenetic Diversity
indicator. b The absolute number of observed species. c The Shannon’s index. d The Chao 1 index
Fig. 4 Differences in the gut microbiota of children infected with S. mansoni after administration of placebo or praziquantel. This cladogram
shows the differences in bacterial composition of infected children receiving a placebo treatment (= Placebo) or infected children with failed
treatment receiving a unique dose of 60 mg/kg praziquantel (= Low)
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Discussion
In this study, we describe for the first time the gut
microbiome changes in S. mansoni-infected children and
their potential impact on treatment outcome based on
oral praziquantel application in an endemic rural area in
Côte d’Ivoire.
Associations between schistosomiasis and the gut
microbiome
Four bacterial phyla are considered to dominate in the
human gut microbiome, including Firmicutes, Bacteroidetes,
Actinobacteria and Proteobacteria [12, 31]. The comparison
of the gut microbiota profiles of children from the health
district of Azaguié in Côte d’Ivoire, whether they were
infected with S. mansoni or not, confirmed this finding.
Abundance ratios of these four dominating phyla are
usually good indicators for dysbiosis and have been
linked to various health conditions, including colitis
and metabolic disorders [32, 33]. Relative abundances
of the different bacterial phyla depicted in this study
correspond to those expected in normal human gut
structure, with Firmicutes > Bacteroidetes > Proteobacteria,
Fig. 5 Comparison of microbiome in the treatment failures versus successful treatment groups. a Before administration of praziquantel. b 24
hours after administration of 60 mg/kg praziquantel. Using the same statistical tests did not reveal any differences of the same groups for the 3
weeks follow-up samples (data not shown)
Fig. 6 Fusobacterium spp. qPCR. a The copy number for Fusobacterium spp. before treatment both in cured and non-cured children. b The
variation in copies number over the 24 hours post-treatment period in both cured and non-cured children
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except for six children infected with schistosomes. While
Proteobacteria are commensals of the gut microbiome, they
are usually present in lower abundance than Firmicutes and
Bacteroidetes in healthy individuals [32]. An outgrowth of
bacteria from this taxon is typical of a major dysbiosis with
clinical relevance, as several bacterial species from this
phylum have been linked with pathogenesis in humans,
resulting in either severe disease burden and/or death
[32, 34–36]. In this specific population, the cumulated
relative abundance of Firmicutes and Bacteroidetes rep-
resents more than 50% of the total bacterial compos-
ition in all but three samples. Interestingly, all three
children, characterized by an untypical microbiome
present a clear dysbiosis towards the phylum Proteobac-
teria and in all cases, the clinical assessment showed an
outcome of clinical relevance, be it blood in stool and
splenomegaly, simple splenomegaly or vomiting within
three hours after praziquantel administration (data not
shown). At the family level, we observed that members
from the clade Prevotellacae, another important group for
healthy gut functionality and which has been linked to
various chronic diseases (e.g. rheumatoid arthritis or obes-
ity), has a highly heterogeneous distribution among our
samples [37, 38].
Diversity indices commonly used in ecological research,
including the phylogenetic diversity, the number of ob-
served species, the Shannon’s and the Chao 1 indices, are
accepted indicators for dysbiosis [39–42]. In our study, we
observed a trend that these different indicators show
an overall lower bacterial diversity in children infected
with S. mansoni. However, the inter-individual diver-
sity varies more in this group and could reflect a less
stable gut microbiota in infected children. This result
fills a gap in our knowledge of associations of intes-
tinal parasites and the gut microbiota structure. To
date it has been shown that different intestinal para-
sites might increase, decrease or have no effect on the
gut microbial diversity [6, 7, 43].
Associations between S. mansoni infection and the usual
indicators of a healthy gut microbiome are relatively sub-
tle. While we observe modifications that seem to be corre-
lated with the presence of schistosomes, both in the phyla
ratios and diversity indicators, the same modifications are
not distributed homogeneously among all infected pa-
tients. This suggests that the gut microbiota stability is af-
fected to some extent by the infection with S. mansoni,
but that other factors, including the host’s specific genetic
makeup in combination with environmental factors, such
as nutrition, play a greater role in the composition of the
gut microbiome, in this context. This observation is in
partial agreement with the conclusion of the recent study
of Kay et al. [44], stating that infection with Schistosoma
haematobium, although being a bladder infecting schisto-
some, is associated with variations in the gut microbiota.
Effect of praziquantel administration on the gut microbiome
Adverse effects from the orally administered praziquantel
are usually mild or moderate and there are gut-related
side effects of praziquantel (abdominal pain, cramps, with
or without nausea and vomiting) that could potentially be
related to a drug-induced microbial dysbiosis [45]. We
compared the gut microbiotas of children 24 hours after
administration of either a placebo or a high single
praziquantel dose (60 mg/kg). The clades Erysipelotri-
chi and Bacilli were overabundant in stools produced
by praziquantel-treated children. For the clade Erysi-
pelotrichi, this information correlates with already
published data, which states that this clade might be
overabundant in patients receiving an antibiotic treat-
ment [46]. Some members from the class Bacilli were
shown to be potentially highly efficient xenobiotic
metabolizers [47, 48]. However, since we did not study
these bacteria at a lower taxonomic level, we cannot
draw a more precise conclusion about this specific ef-
fect. At the time of this study, no published data were
available linking either Erysipelotrichi or Bacilli clades
to gastrointestinal complications. Therefore, since the
structural changes in microbiota composition remain
moderate and restricted to these two clades, we hypothesize
that they do not contribute to the gut-related side effects of
praziquantel administration. We can therefore conclude
that praziquantel-related side effects are not related to
indirect effects on the gut microbiome and that they are
mostly explained by other factors, potentially including ex-
pulsion of dead S. mansoni adult worms, host’s genetics
and/or degradation of S. mansoni eggs triggering the host’s
inflammatory response, as previously shown [49, 50]. This
observation, while based on a restricted amount of samples,
gives new insights on conclusions made in a previous study
on off-target effects of praziquantel [44]. While the study of
Kay et al. [44] shows that praziquantel does not have an ef-
fect on the gut microbiota in the long term (12 weeks post-
administration), we complement this information by stating
that praziquantel does in fact have a slight short-term effect
(24 hours post-administration) on the gut microbiota.
Differences in the microbiome of successful versus failed
treatments
As a final part of this study, we investigated potential
bacterial factors in the gut microbiome that might explain
the variations in treatment response to praziquantel. For
this purpose, we stratified the samples from infected chil-
dren into two groups based on the cure rates observed
within the 3-week follow-up period. Of note, non-cured
children showed on average an egg reduction rate of <
60%, which is way below the reference drug efficacy value
of ≥ 90% set by WHO, hence praziquantel did not fulfil
the criteria of clinical efficacy in these children. However,
key pharmacokinetic parameters (AUC, Cmax) did not
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show a significant difference between cured and not cured
children (data not shown) hence we can rule out that chil-
dren did not take the treatment.
At baseline, the main differences were driven partly by
endosymbionts of plant cells from the classes Rickettsiales
and Neisseriales. For both classes, there is no specific litera-
ture describing their potential to modulate xenobiotics
metabolism. Members from the class Fusobacteriales were
also significantly more abundant in the successfully treated
group at baseline. Twenty-four hours post-treatment, it is
interesting to note that members from the same class were
still significantly more abundant in the treatment success
group. The qPCR assays confirmed a significant difference
in the abundance of the genus Fusobacterium, a genus
populated with potential pathogens, in the pre-treatment
samples, between cured and non-cured patients [51]. This
genus is particularly interesting as it includes species known
to have inflammatory properties and species that have been
linked to chronic disease, such as Fusobacterium nuclea-
tum, that could be closely associated with the worm-
triggered inflammatory response [52, 53]. Our results indi-
cate that high Fusobacterium spp. abundance before treat-
ment and high decrease rate of the bacteria over the first 24
hours post-treatment is correlated with a better outcome of
praziquantel treatment. This could indicate that Fusobac-
terium spp. abundance and S. mansoni infection are dy-
namically linked and that preliminary presence of
Fusobacterium spp. might condition the outcome of schis-
tosomiasis treatment while being independent from the
drug itself.
Limitations
While this study does show preliminary results on gut
composition related differences that may explain dis-
crepancies in treatment outcome with praziquantel, it
remains based on this specific paediatric population
and a larger cohort is needed to confirm these results.
For instance, additional patients with low-intensity of
infection and high cure rate would be needed to draw
significant conclusions as to what pertains the impact
of different intensity of infections with S. mansoni on
the gut microbiota. Also, additional investigations are
required to fully understand the potential role and
mechanism of action of these factors on praziquantel
efficacy against schistosomiasis.
Conclusions
This study highlighted three aspects of the interrelations
between S. mansoni, praziquantel and the gut micro-
biota, namely; (i) the associations of S. mansoni and the
usual indicators for a healthy gut microbiome seem to
lay more in subtle modifications than in major compos-
itional shifts. While we observed some modifications in
the gut microbiome that seem to be specific to the
presence of S. mansoni, the same modifications were not
distributed evenly among infected patients; (ii) prazi-
quantel administration had, similarly, relatively moderate
effects on the gut microbiome. The observed effects on
the microbiota are limited to two bacterial groups for
which there is, so far, no proof of pathogenesis in human
in the literature, but rather associations with responses
to drug treatment. Therefore, we conclude that the
gastrointestinal side effects observed in praziquantel ad-
ministration are not related to an off-target effect of
the drug on the microbial communities in the gut; and
(iii) we were also able to highlight a bacterial taxon
that could potentially play a role in the variations ob-
served for schistosomiasis treatment outcomes with
praziquantel, namely Fusobacterium spp. Further in-
vestigations are needed to understand and characterize
the role of Fusobacterium spp. and their role in oral
praziquantel treatment success.
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